Loading
A phase 1/2 trial of Fulvestrant and Palbociclib in advanced solid tumours, run by Pikavation Therapeutics, Inc., now recruiting.
SNV4818 in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06736704 by Pikavation Therapeutics, Inc., with 320 participants planned, started 2025-02-20 and due to reach its primary completion in 2027-04. Interventions recorded: SNV4818, Fulvestrant and Palbociclib.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Palbociclib, Fulvestrant and the tag pipeline.
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/